Literature DB >> 26122867

Left ventricular remodeling in patients with sickle cell disease: determinants factors and impact on outcome.

Maria Carmen M Vasconcelos1, Maria Carmo P Nunes, Marcia M Barbosa, Bárbara Martins Fernandes, Luiz Guilherme Passaglia, Célia Maria Silva, Teresa Cristina A Ferrari.   

Abstract

Cardiovascular complications have been increasingly detected as a result of prolonged longevity of patients with sickle cell disease (SCD). Previous studies have focused especially on pulmonary hypertension and its consequences on the right-side heart chambers, whereas factors associated with morphological changes in left ventricle (LV) remain poorly understood. This study was designed to identify clinical, laboratorial, and echocardiographic parameters associated with LV remodeling and its impact on outcome in SCD. Ninety patients aged 28 ± 7 years and 20 age- and gender-balanced healthy subjects were enrolled. Laboratory tests, electrocardiogram, and an echocardiogram with tissue Doppler imaging were performed in all patients. Patients with SCD had larger left and right heart chambers dimensions, LV mass, and tricuspid regurgitation (TR) velocity compared to health controls with similar demographic features. Despite chambers enlargement, systolic function of both ventricles was preserved. The mitral inflow velocities were higher in the patients than in controls, whereas septal and lateral annular motion velocities were normal, suggesting normal ventricular relaxation. SCD patients who were on hydroxyurea therapy and/or hypertransfusion had higher hemoglobin concentrations, but similar echocardiographic findings in comparison to those without treatment. Systolic blood pressure, ferritin concentration, TR velocity, and parameters of diastolic function were independently associated with increased LV mass. In addition, the predictors of adverse events were ferritin concentration, lactate dehydrogenase levels, and TR velocity. LV remodeling in SCD patients seems to be influenced by a combination of factors including blood pressure, ferritin concentration, TR velocity, and parameters of LV diastolic function, and was not associated with adverse outcomes.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26122867     DOI: 10.1007/s00277-015-2430-z

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  6 in total

1.  Reversal of a rheologic cardiomyopathy following hematopoietic stem cell transplantation for sickle cell disease.

Authors:  Vandana Sachdev; Matthew Hsieh; Neal Jeffries; Anna Noreuil; Wen Li; Stanislav Sidenko; Hwaida Hannoush; Emily Limerick; Delon Wilson; John Tisdale; Courtney Fitzhugh
Journal:  Blood Adv       Date:  2019-10-08

2.  Relationship between pulmonary and cardiac abnormalities in sickle cell disease: implications for the management of patients.

Authors:  Maria Christina Paixão Maioli; Andrea Ribeiro Soares; Ricardo Bedirian; Ursula David Alves; Cirlene de Lima Marinho; Agnaldo José Lopes
Journal:  Rev Bras Hematol Hemoter       Date:  2015-12-11

3.  Speckle tracking evaluation of right ventricular functions in children with sickle cell disease.

Authors:  Osama Abd Rab Elrasol Tolba; Mohamed Ramadan El-Shanshory; Mohamed Abd Elaziz El-Gamasy; Walid Ahmed El-Shehaby
Journal:  Ann Pediatr Cardiol       Date:  2017 Sep-Dec

4.  Evaluation of Cardiac Function in Patients with Sickle Cell Disease with Left Ventricular Global Longitudinal Strain.

Authors:  Marielle Morissens; Tatiana Besse-Hammer; Marie-Agnès Azerad; Andre Efira; José Castro Rodriguez
Journal:  J Transl Int Med       Date:  2020-05-09

5.  Cardiac Chamber Quantification by Echocardiography in Adults With Sickle Cell Disease: Need Attention to Eccentric Hypertrophy.

Authors:  Mahmut B Koyuncu; Anil Tombak; Ozcan Orscelik; Tolga Koseci; Ali Turker; Hakan Basir; Aydan Akdeniz; Eyup N Tiftik
Journal:  Cureus       Date:  2021-06-11

6.  Computer Algorithm-Based Hydroxyurea Dosing Facilitates Titration to Maximum Tolerated Dose in Sickle Cell Anemia.

Authors:  Mahogany Oldham; Anna Conrey; Corinne Pittman; Cameron Fisher; Simone Hargrett; Kamille West; Mary Jackson; Staci Martin; Matthew M Hsieh; Neal Jeffries; Mihailo Kaplarevic; Dachelle Johnson; Purevdorj Olkhanud; Courtney D Fitzhugh
Journal:  J Clin Pharmacol       Date:  2020-07-16       Impact factor: 2.860

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.